Zacks: Neurotrope Inc (NTRP) Receives Consensus Recommendation of “Strong Buy” from Brokerages
Neurotrope Inc (NASDAQ:NTRP) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus target price of $16.00 for the company, according to Zacks. Zacks has also given Neurotrope an industry rank of 184 out of 255 based on the ratings given to its competitors.
A number of research analysts have recently issued reports on the stock. Maxim Group set a $16.00 price target on shares of Neurotrope and gave the stock a “buy” rating in a research report on Monday, July 2nd. Zacks Investment Research upgraded shares of Neurotrope from a “sell” rating to a “hold” rating in a research report on Thursday, June 28th. Finally, ValuEngine downgraded shares of Neurotrope from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd.
NTRP traded down $0.51 during trading on Tuesday, reaching $8.05. 23,100 shares of the company’s stock were exchanged, compared to its average volume of 26,085. Neurotrope has a one year low of $3.97 and a one year high of $11.93.
Neurotrope (NASDAQ:NTRP) last issued its quarterly earnings results on Friday, August 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.12.
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.
Further Reading: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.